Tus-Pharmaceutical Group Co., Ltd.

000590.SZ

000590.SZTus-Pharmaceutical Group Co., Ltd.

Shenzhen

5.34

CNY

-0.08

(-1.48%)

-0.02EPS

-267.00P/E

1.28BMarket Cap

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

Tus-Pharmaceutical Group Co., Ltd.

000590.SZ

(Shenzhen)

Recent

price

5.34

P/E

ratio

-267

div

yld

- -

ROIC.AI

Legends:

Stock price

Beta (1.0 Market)

% total return 09/17

Stock

S&P500

-39.18

26.92

-38.27

27.56

-54.28

87.11

2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	TTM
1.06	1.23	1.4	1.54	1.63	1.15	0.91	1.32	1.42	1.48	0.78	1.32	1.15	1.26	1.46	1.69	1.51	Revenue per Share
0.07	-0.39	0.21	0.32	0.62	-0.74	-0.38	0.1	0.25	0.08	-0.16	0.18	0.09	0.15	0.08	0.11	-0.02	Basic EPS, GAAP
0.09	0.07	0.27	0.04	0.02	-0.05	-0.62	-0.41	-0.22	-0.48	-0.09	-0.03	0.07	- -	0.15	-0.21	-0.09	Free Cash Flow per Basic Share
0.05	0.03	0.02	0.02	0.09	0.2	0.02	0.01	- -	- -	0.01	0.01	- -	- -	- -	0.02	0.02	Dividend per Share
0.81	0.42	0.63	0.83	1.25	0.32	-0.07	0.03	0.28	0.42	0.25	0.43	0.52	0.67	0.75	0.85	0.75	Book Value per Share
0.79	0.41	0.64	1.02	1.55	0.55	0.13	0.07	0.38	1.79	1.85	2.04	2.12	2.29	1.7	1.94	1.85	Tangible Book Value per Share
223	223	223	223	223	223	223	223	223	233	240	240	239	239	240	240	239	Basic Weighted Avg Shares
237	274	312	344	363	256	203	295	317	344	186	315	275	301	351	405	361	Sales/Revenue/Turnover
17.28	9.82	21.7	26.5	12.92	-23.98	-29.36	12.1	7.81	4.82	-19.25	8.81	8.14	11.34	4.62	5.06	-2.05	Operating Margin (%)
13	14	14	15	17	17	13	14	15	14	16	14	14	19	24	28	- -	Depreciation Expense
17	-88	47	72	138	-164	-86	22	55	19	-38	42	23	35	18	25	-5	Net Income, GAAP
29.4	- -	15.58	17.96	25.31	- -	- -	27.53	24.36	55.12	- -	20.59	17.8	15.29	17.09	16.14	32,666.12	Effective Tax Rate (%)
7.02	-32.05	15.13	21	37.86	-64.24	-42.23	7.59	17.38	5.58	-20.55	13.47	8.26	11.78	5.17	6.24	-1.25	Profit Margin (%)
22	-69	-52	-9	175	36	-63	-26	30	358	346	338	348	367	258	291	270	Working Capital
14	10	- -	- -	- -	- -	- -	- -	- -	20	20	- -	9	6	95	83	85	LT Debt
319	231	279	361	479	270	184	206	264	583	580	622	645	682	702	728	705	Total Equity
6.6	- -	18.94	22.1	8.81	- -	- -	15.6	8.78	1.9	- -	4.12	3.31	4.9	1.92	2.2	307.61	Return on Invested Capital (%)
9.57	- -	25.8	33.37	52.93	- -	- -	37.89	57.91	21.93	- -	43.76	18.84	23.12	7.82	9.47	-443.36	Return on Capital (%)
9.57	-63.61	40	44.03	59.05	-93.76	- -	- -	157.48	23.88	-48.42	52.41	20.01	24.84	10.69	13.21	-2.48	Return on Common Equity (%)

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	9.26%	19.64%	15.44%
Net Income, GAAP	-60.28%	-42.23%	39.41%
Free Cash Flow	-501.82%	-1,230.21%	-243.71%
Total Cash Common Dividend	128.45%	286.83%	1,139.73%
Total Equity	15.21%	4.68%	3.66%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Business: Tus-Pharmaceutical Group Co., Ltd. manufactures and sells traditional Chinese medicine and western medicine products. The company was formerly known as Tus-Guhan Group Corp.,Ltd. Tus-Pharmaceutical Group Co., Ltd. was founded in 1956 and is based in Hengyang, China.

	Dec'23	Mar'24	Jun'24
ST Debt	12	37	11
LT Borrowings	80	80	80
LT Finance Leases	3	5	5
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	239	239	239
Market Capitalization	2,145	1,786	1,262

	Dec'23	Mar'24	Jun'24
Total Current Assets	540	554	517
Accounts Receivable, Net	22	16	14
Cash, Cash Equivalents & STI	190	167	201
Inventories	130	150	148
Total Current Liabilities	249	267	247
Payables & Accruals	- -	- -	- -
ST Debt	12	37	11
Deferred Revenue	- -	- -	- -

2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	TTM
1.06	1.23	1.4	1.54	1.63	1.15	0.91	1.32	1.42	1.48	0.78	1.32	1.15	1.26	1.46	1.69	1.51	Revenue per Share
0.07	-0.39	0.21	0.32	0.62	-0.74	-0.38	0.1	0.25	0.08	-0.16	0.18	0.09	0.15	0.08	0.11	-0.02	Basic EPS, GAAP
0.09	0.07	0.27	0.04	0.02	-0.05	-0.62	-0.41	-0.22	-0.48	-0.09	-0.03	0.07	- -	0.15	-0.21	-0.09	Free Cash Flow per Basic Share
0.05	0.03	0.02	0.02	0.09	0.2	0.02	0.01	- -	- -	0.01	0.01	- -	- -	- -	0.02	0.02	Dividend per Share
0.81	0.42	0.63	0.83	1.25	0.32	-0.07	0.03	0.28	0.42	0.25	0.43	0.52	0.67	0.75	0.85	0.75	Book Value per Share
0.79	0.41	0.64	1.02	1.55	0.55	0.13	0.07	0.38	1.79	1.85	2.04	2.12	2.29	1.7	1.94	1.85	Tangible Book Value per Share
223	223	223	223	223	223	223	223	223	233	240	240	239	239	240	240	239	Basic Weighted Avg Shares
237	274	312	344	363	256	203	295	317	344	186	315	275	301	351	405	361	Sales/Revenue/Turnover
17.28	9.82	21.7	26.5	12.92	-23.98	-29.36	12.1	7.81	4.82	-19.25	8.81	8.14	11.34	4.62	5.06	-2.05	Operating Margin (%)
13	14	14	15	17	17	13	14	15	14	16	14	14	19	24	28	- -	Depreciation Expense
17	-88	47	72	138	-164	-86	22	55	19	-38	42	23	35	18	25	-5	Net Income, GAAP
29.4	- -	15.58	17.96	25.31	- -	- -	27.53	24.36	55.12	- -	20.59	17.8	15.29	17.09	16.14	32,666.12	Effective Tax Rate (%)
7.02	-32.05	15.13	21	37.86	-64.24	-42.23	7.59	17.38	5.58	-20.55	13.47	8.26	11.78	5.17	6.24	-1.25	Profit Margin (%)
22	-69	-52	-9	175	36	-63	-26	30	358	346	338	348	367	258	291	270	Working Capital
14	10	- -	- -	- -	- -	- -	- -	- -	20	20	- -	9	6	95	83	85	LT Debt
319	231	279	361	479	270	184	206	264	583	580	622	645	682	702	728	705	Total Equity
6.6	- -	18.94	22.1	8.81	- -	- -	15.6	8.78	1.9	- -	4.12	3.31	4.9	1.92	2.2	307.61	Return on Invested Capital (%)
9.57	- -	25.8	33.37	52.93	- -	- -	37.89	57.91	21.93	- -	43.76	18.84	23.12	7.82	9.47	-443.36	Return on Capital (%)
9.57	-63.61	40	44.03	59.05	-93.76	- -	- -	157.48	23.88	-48.42	52.41	20.01	24.84	10.69	13.21	-2.48	Return on Common Equity (%)

Tus-Pharmaceutical Group Co., Ltd.

Growth Rates

(avg. rate of change)

Capital Structure

Working Capital

Growth Rates

(avg. rate of change)

Quarterly Dividends Per Share

Year

Quarterly Earnings Per Share

Year

Quarterly Revenue

Year